Altered cytoplasmic and nuclear ADP‐ribosylation levels analyzed with an improved ADP‐ribose binder are a prognostic factor in renal cell carcinoma

Altered cytoplasmic and nuclear ADP‐ribosylation levels analyzed with an improved ADP‐ribose binder are a prognostic factor in renal cell carcinoma

Abstract ADP‐ribosylation (ADPR) of proteins is catalyzed by ADP‐ribosyltransferases, which are targeted by inhibitors (i.e. poly(ADP‐ribose) polymerase inhibitors [PARPi]). Although renal cell carcinoma (RCC) cells are sensitive in vitro to PARPi, studies on the association between ADPR levels and...

Full description

Bibliographic Details
Main Authors: Peter Schraml, Fabio Aimi, Martin Zoche, Domingo Aguilera‐Garcia, Fabian Arnold, Holger Moch, Michael O Hottiger
Format: Article
Language:English
Published: Wiley 2023-07-01
Series:The Journal of Pathology: Clinical Research
Subjects:
ADP‐ribosylation
PARP
inhibitors
kidney
cancer
Online Access:https://doi.org/10.1002/cjp2.320

Internet

https://doi.org/10.1002/cjp2.320

Similar Items